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Abstract The field of plasma medicine has seen substantial
advances over the last decade, with applications developed for
bacterial sterilisation, wound healing and cancer treatment.
Low temperature plasmas (LTPs) are particularly suited for
medical purposes since they are operated in the laboratory at
atmospheric pressure and room temperature, providing a rich
source of reactive oxygen and nitrogen species (RONS). A
great deal of research has been conducted into the role of
reactive species in both the growth and treatment of cancer,
where long-established radio- and chemo-therapies exploit
their ability to induce potent cytopathic effects. In addition
to producing a plethora of RONS, LTPs can also create strong
electroporative fields. From an application perspective, it has
been shown that LTPs can be applied precisely to a small
target area. On this basis, LTPs have been proposed as a prom-
ising future strategy to accurately and effectively control and
eradicate tumours. This review aims to evaluate the current
state of the literature in the field of plasma oncology and
highlight the potential for the use of LTPs in combination
therapy. We also present novel data on the effect of LTPs on
cancer stem cells, and speculatively outline how LTPs could
circumvent treatment resistance encountered with existing
therapeutics.
Keywords Lowtemperatureplasma .Reactivespecies .Focal
therapy . Cancer stem cells . Combination therapy
Introduction
The role of reactive species in cancer initiation, progression
and treatment has been intensively researched over the last
few decades. The mechanistic actions of radio- and chemo-
therapies frequently rely on the formation of reactive species,
and they have been proposed as a means to preferentially
target malignant cells [1]. Low temperature plasmas are
known to generate a plethora of reactive oxygen and nitrogen
species [2], and could present an exciting newmodality for the
treatment of tumours.
Plasmas are ionised gases, comprising a complex environ-
ment of charged particles, neutral gas molecules, UV radiation,
electric fields and reactive species. They occur widely in nature
(for example as lightning or the aurora borealis), yet can also be
created in many forms in the laboratory to exploit their unique
properties for many varied applications, from surface modifica-
tion to clean energy production. Due to technological advance-
ments, it has become possible to sustain plasmas at atmospheric
pressure and room temperature. This has enabled the use of
plasmas in a range of technological and biomedical applications,
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and thus the conception of the field of ‘plasma medicine’ over
the last decade. ‘Low temperature plasmas’ (LTPs) are very
weakly ionised; the electrons, which can have temperatures
∼104 K and drive the plasma processes, make up a very small
fraction of the plasma (<0.1 %). The bulk of the plasma consists
mainly of background neutral gas atoms andmolecules, and due
to the inefficient energy transfer between the light electrons and
‘heavy’ neutrals, the global environment remains at room tem-
perature. This aspect allows the application of LTPs to
temperature-sensitive materials, such as living tissues.
The general concept of plasmas in medicine is not totally
new, as they have been utilised as electrosurgical instruments
in medical practice for a number of years and in a range of
procedures [3]. Recent innovations include instruments from
Plasma Surgical and Arthrocare; hand-held devices capable of
vaporising, sealing and dissecting tissues [4, 5]. LTPs are fun-
damentally different; as their name suggests, they do not uti-
lise thermal effects to induce biological response. Instead, they
induce biological response through the production of reactive
species and potentially strong electric fields, and are a novel
proposition for use in medical procedures. A sketch and pho-
tograph of a typical laboratory LTP jet set-up is shown in
Fig. 1. Controlled gas flow is fed through glass tubing, around
which high-voltage electrodes are positioned. The core plasma
is ignited between these electrodes by applying a high voltage
(typically up to 20 kV), and a plasma jet then propagates
outwards and can interact with the biological sample. It is
important to note that Fig. 1 represents only a single example;
many different LTP designs and geometries exist that are
intended for biomedical applications [7–11].
This review paper aims to highlight recent progress in the
field of plasma oncology, and will present LTPs as a promis-
ing tool for future focal cancer treatment. Comparisons are
made between the mechanisms of existing therapies and
how the properties of LTPs could lead to more favourable
treatment outcomes. The prospect of combining LTPs with
existing therapies and technologies to exploit potential syner-
gies is outlined, as well as a speculative view suggesting how
LTPs may be capable of overcoming treatment resistance. We
also present novel data on the cytotoxic effect of LTP on
cancer stem cells cultured directly from an aggressive prostate
tumour. Finally, introduction of LTPs into clinical practice is
evaluated, and the logistics of patient treatment is discussed.
Low temperature plasmas as a source of reactive
species
Mounting evidence in the scientific and medical literature
suggests that LTPs rely strongly on the formation of reactive
species to facilitate cellular responses. Processes such as
ionisation, dissociation, excitation and recombination of
atoms and molecules within the plasma lead to a chemically
rich environment of reactive oxygen species (ROS) including
atomic oxygen (O) [12, 13], hydroxyl (OH) [14], superoxide
(O2
−)[15], singlet-delta oxygen (1O2) [16] and hydrogen per-
oxide (H2O2) [17]. In addition, depending upon the gas com-
position and plasma geometry, reactive nitrogen species
(RNS) may include atomic nitrogen (N) [18], nitric oxide
(NO) [19], peryoxynitrite (ONOO−) [20] and other members
Fig. 1 Schematic representation
of low temperature plasma
formation and application. Gas
flow is ignited by high voltage
applied across ring electrodes.
The core plasma propagates from
the end of the tube and is applied
into a bulk tumour, causing DNA
damage through the formation of
reactive oxygen and nitrogen
species. Note: this diagram is not
to scale; in the accompanying
image, the dimensions of central
quartz glass tube are 70 × 6 mm.
Elements of this figure are
modified from Hirst et al. [6]
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of the NOx family. The multitude of RONS generated by LTPs
could provide significant advantages over other cancer thera-
pies, e.g. radiotherapy and photodynamic therapy, which gen-
erally produce only ROS. Indeed, high concentrations of NO
has been suggested to preferentially induce apoptosis in tu-
mour cells, implying the action of nitrosative stress could
prove crucial to successful cancer therapy [21].
The involvement of ROS in cancer initiation and progres-
sion [22], and their therapeutic potential [23] have been ac-
tively researched for many years. The cellular threat from low
levels of ROS is well tolerated and neutralised through the
action of enzymes including super oxide dismutase and cata-
lase [24]. The inherent elevated metabolic activity in malig-
nant cells (Warburg effect) may present a therapeutic window,
as they are essentially already at their ROS-tolerance threshold
or ‘red-line’ when compared with neighbouring normal cells
[1, 25]. The creation of high levels of ROS is the mechanism
by which long-established anti-tumour strategies, such as
radio- [26] and some chemo-therapies [27, 28], operate to
induce oxidative stress which result in cytopathic cellular re-
sponses. Given that LTPs create a multitude of reactive oxy-
gen and nitrogen species (RONS) [29], they are an obvious
candidate for cancer therapy; potentially being more effica-
cious than treatments which only involve ROS. This concept
is discussed further in the context of treatment resistance in a
later section.
The application of LTP to cells or tissues is a multi-phase
process, which begins with an initial ignition and steady-state
core plasma, followed by an afterglow plasma phase, leading
to a diffusive interface with a liquid-like layer or environment.
The liquid environment can either be represented by treatment
of the cell culture media in laboratory experiments, or more
physiologically the fluid within and surrounding a tumour in a
clinical plasma application. This plasma-modified liquid en-
vironment then influences the cells and tissues around it. An
illustrative overview of this process is depicted in Fig. 2, along
with approximate time-scales for various phenomena in the
plasma and liquid phases, and subsequent biological
interaction.
The dynamics of the chemistry within the plasma core are
extremely complex. Global models have been developed to
capture this, which comprise in excess of 60 different species,
involved in ∼1000 different reactions [2]. Translation to the
liquid environment and ultimately a precise understanding of
the specific extra- and intra-cellular RONS involved in both
cellular effect and response, and their concentrations is vastly
more so. Predictive numerical models have attempted to re-
solve and understand this complexity, including both the var-
iation in chemistry between the gas-liquid-tissue phases [30],
the fluxes of different reactive species at the tissue surface
[31], and the influence of different molecular gas admixtures
[13, 18, 32]. The mechanistic effects of LTPs on cells are
presented in the following section.
Mechanisms of LTP—cell interaction and response
LTPs create and transfer numerous RONS to the cellular en-
vironment, as discussed earlier. Current evidence implies that
the production of RONS is primarily responsible for cytopath-
ic effects of the plasma. However, other facets of LTPs may
contribute to ultimate cell fate and treatment outcome.
LTPs have been applied to a range of different malignant
cell lines in culture with extremely promising results. A range
of common cellular responses have been documented includ-
ing DNA damage [33, 34], decreased cell viability and
clonogenicity [35, 36], reduced proliferation [37] and cell cy-
cle arrest [38, 39]. From the growing literature, it would ap-
pear the cell death mechanism following LTP treatment varies
with both the cell type and plasma source used. The vast
majority of studies report apoptosis [19, 37, 40–43]; however,
senescence [44] and non-apoptotic cell death [36] have also
been presented. A summary of experimental approaches to
cell treatment and subsequent cell death mechanism is given
in Table 1. The studies presented therein were selected to
reflect the different types of plasma, exposure times and ap-
proaches to treatment adopted within the field, and how these
might relate to the observed outcomes. Elevated RONS levels
are continually cited as the likely perpetrators of plasma-
induced effects, leading to the activation of apoptotic path-
ways including TNF-ASK1 [46], ATM/p53 [19] and MAPK
[15]. Furthermore, LTP effects have been shown to be (at least
partially) alleviated by the use of various RONS scavengers
[19, 47], further confirming the central role of reactive species
produced by LTPs. Despite this, strong electric fields pro-
duced by some LTPs may play an important, synergistic role
in plasma-cell interaction [48] and are discussed further in a
later section.
Many investigators report a selective effect following LTP
treatment, i.e. the plasma-effect preferentially targets tumour
cells and leaves normal cells relatively unscathed [36, 49].
This is without doubt a highly desirable, ‘gold standard’ out-
come. One explanation may be the rapidly dividing nature of
tumour cells, increasing their vulnerability to DNA damage in
M-phase [50], and/or the different tolerances of normal and
cancer cells to elevated ROS levels [25] as alluded to earlier.
The latter may explain a recent observation of an elevated
autophagic response of normal cells when compared to tu-
mour cells [17]. However, a more simple explanation may
be the comparison of different cell types, for example normal
fibroblasts with epithelial cancer cells, which may have quite
different response profiles.
LTPs have also been applied to three-dimensional cell line
models including spheroids and murine xenografts. Surface
treatment of glioma xenografts with LTP showed a significant
reduction in tumour volume, facilitated by ROS-induced
caspase-3-dependent cell death [45]. In an earlier study, the same
group showed that LTP treatment of tumours resulted in a 58 %
Tumor Biol.
Table 1 LTP treatment induces different paths to cell death. Summary of assorted cell treatment methods and associated death mechanisms for a range
of malignancies
Cancer type Method of treatment Treatment duration Cell death mechanism Reference
Prostate cancer cell lines:
PC-3 and LNCaP
In suspension, 500 μl volume 10 s Apoptosis Weiss et al. [37]
Glioma cell lines: U87, U373, A172 Adherent cells, 96-well plates,
∼40 % confluence
Up to 180 s Apoptosis/necrosis Siu et al. [40]
Lymphoma cell line: U937 Adherent cells, 10 cm plates,
5 ml volume
Up to 480 s Apoptosis Kaushik et al. [42]
Malignant cell lines from various sites Adherent cells, 35 mm plates 30–60 s, up to 10
repeated exposures
Apoptosis Ma et al. [19]
Colorectal cancer cell lines:
Caco2, HCT116, SW480 and HT29
Adherent cells in various
multi-well culture plates
Up to 30 s Apoptosis Ishaq et al. [41]
Glioma and colorectal cancer cell lines:
U87MG-Luc2 and HCT-116-Luc2.
Adherent cells, 24-well plates,
500 μl volume
Up to 30 s Apoptosis Vandamme et al. [45]
Glioma xenografts: U87MG-Luc2 Subcutaneous tumours 6 min daily for 5
consecutive days
Apoptosis
Head and neck cancer cell lines: FaDu,
SNU1041, SNU899 and HN9
In suspension, 6 cm plates,
3 ml volume
1 s at either 2 or 4 kV Apoptosis Kang et al. [15]
FaDu xenografts Subcutaneous tumours 20 s daily for 20 days Apoptosis
Various melanoma cell lines Adherent cells, assorted culture
plates, without culture medium
Up to 120 s Senescence Arndt et al. [44]
Prostate cancer primary epithelial cells In suspension, 1.5 ml volume Up to 600 s Necrosis, autophagy Hirst et al. [17]
Fig. 2 An illustrative representation of the multi-phase transfer of plasma
species towards a biological sample. The main components of the plasma
phase, including ions, photons and neutral species, are shown, leading to
the creation of various RONS across the plasma-liquid interface and their
propagation towards and diffusion through an arbitrary tissue layer. In
addition, approximate timescales governing various phenomena across
the plasma-liquid phases and biological interaction are outlined
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increased lifespan over untreated mice [51]. Application of LTP
in an in vivo head and neck cancer cell line model showed
significant reduction in tumour mass and volume, verified by
DNA fragmentation and caspase-3 positive staining, indicative
of apoptosis through activation of p38 and JNK [15].
A recent study showed that primary prostate cells, cultured
directly from patient tissue samples, rapidly underwent necrosis
following exposure to LTP [17]. In addition, the effect on both
normal and cancer prostate cells from the same patient was large-
ly comparable. These findings imply that (a) primary cells may
respond quite differently to LTP treatment than the broadly apo-
ptotic response found in various cell lines, and (b) selective plas-
ma effects may be less pronounced when LTP is applied to
patients. Clearly, further verification of primary cells and primary
xenografts from various tumour sites will provide further insight
into patient response to LTP. The safe application of LTP to
cancerous ulcers has been demonstrated for palliative purposes,
but also showed partial tumour remission in some patients [52].
Direct and uniform exposure of all cells within a bulk tu-
mour population to LTP treatment would be extremely tech-
nically challenging. However, it is conceivable that cell-to-cell
communication will play a role in LTP treatment of a tumour.
Radiation-induced bystander effects (RIBEs) are well docu-
mented following DNA damaging events and associated ele-
vation in ROS levels in irradiated cells, which lead to extra-
cellular stress-signalling to neighbouring non-irradiated cells
[53]. Given that LTPs are known to inflict comparable initial
cytotoxic effects on tumour cells, it would therefore seem
logical to anticipate a similar plasma-induced bystander effect
following LTP treatment [54].
Although much of the focus of plasma medicine studies
centre around elevated ROS levels and their effects, the forma-
tion of strong localised electric fields by LTPs can also occur.
Thesemay interact directly with cell membranes and thus cause
similar effects to those of emerging electroporative cancer
therapies. Electroporation treatments utilise strong electric
fields to irreversibly compromise cell membranes to provoke
a cytocidal response. Nanoknife technology has been proposed
for focal treatment of pancreatic [55], prostate [56] and renal
cancers [57]. Numerical modelling has suggested that LTPs
may create electric fields in the hundreds of kilovolt/
centimetre (kV/cm) range [58], capable of penetrating a few
cell layers, and generating sufficiently high fields within indi-
vidual cells for electroporative effects [59]. The geometry and
type of plasma will determine the presence and strength of the
electric field. Novel methods and diagnostic techniques have
quantified average field strengths of around 10–20 kV/cmwith-
in LTPs, but locally thesemay rise towards 100 kV/cm [60, 61].
Crucially, electric field strength has recently been determined
for plasmas propagating through elongated capillaries [48]; the
importance of which is discussed later. Electroporative effects
have indeed been demonstrated biologically following plasma
treatment [62], which may irreversibly damage cell membranes
and aid the transfer of RONS into the cell, as well as permitting
leakage of intra-cellular components. In some circumstances,
plasmas can also generate focussed shockwaves that propagate
through solutions (and into tissues), which have been shown to
induce cell death in vivo [63].
Combination of LTP treatment with existing cancer
therapies to exploit synergistic gains
Whilst LTPs show clear potential to be an effective future
cancer therapy in their own right, their efficacy could be fur-
ther enhanced by combining them with existing treatment
modalities. A recent study showed that a low temperature
plasma gun was more effective than the chemotherapeutic
agent gemcitabine in reducing both tumour volume and mass
in an orthotopic pancreatic cancer model [64]. However, al-
ternating plasma treatment with the drug saw further signifi-
cant increases in treatment efficacy. This poses the possibility
of combining plasma treatments with current standard treat-
ment modalities, which may exploit potential additive or syn-
ergistic effects, leading to improved treatment outcomes.
LTPs may also be considered as an alternative option to treat
malignancies that are resistant to the conventional treatment
approaches. One example is temozolomide (TMZ), the standard
initial chemotherapeutic agent prescribed to glioblastoma patients.
However, tumours which express high levels of the enzyme O6-
methylguanine-DNA methyltransferase (MGMT) show high
resistance to TMZ [65].When treated with LTP, glioblastoma cell
lines (including MGMT-positive cells) showed reduced viability
and clonogenicity, cell-cycle arrest, and ultimately apoptosis far in
excess of TMZ-treated control cells [66]. A similar finding was
observed in a chemo-resistant hepatocarcinoma model, where
treatment with LTP lead to significant cytotoxic effects [67].
This demonstrates the potential for the use of LTPs as a salvage
treatment option for patients who have failed the standard treat-
ment approach, or perhaps pre-emptively in tumours that are
known to be resistant to certain agents.
Recent studies have demonstrated the use of gold nanopar-
ticles (AuNPs) for targeted delivery into tumour cells as drug
carriers [68] or radiosensitisers [69]. AuNPs may also provide
a means to effectively target cancer stem cells (CSCs) [70], a
small population of cells believed by many to be the root of
treatment resistance and recurrence, which is discussed further
in the following section. The potential of AuNPs has led plas-
ma physicists to investigate their use in conjunction with LTPs
[71]. When utilised together, the combination AuNPs with
LTP treatment enhanced efficacy beyond that of either agent
alone in glioblastoma cells [72]. Treatment with LTP may also
increased the uptake of AuNPs into malignant cells [73]. The
amalgamation of LTPs and AuNPs may also present an op-
portunity to increase the cytotoxic selectivity of LTP towards
tumour cells [74, 75].
Tumor Biol.
The exact mechanism of plasma-induced cytopathic ef-
fects could prove crucial to the long-term success of any
prospective anti-cancer treatment, broadly speaking: apopto-
sis or necrosis. Apoptotic cell death is potentially immuno-
suppressive and thus can assist immune system evasion of the
tumour [76, 77]. However, in several pre-clinical studies ad-
dressing the combination of radio- and immuno-therapies to
improve therapeutic potential [78], it has been shown that
necrotic cell death can increase tumour immunogenicity
through induction of heat shock protein expression [79].
Moreover, necrosis is induced by thermally ablative treat-
ments such as cryotherapy [80], radiofrequency ablation
[81] and HIFU [82], and is known to cause local inflamma-
tion at the treatment site. As mentioned previously, it has
recently been demonstrated that prostate cancer cells cultured
directly from patient tissue samples and treated with LTP
rapidly initiate necrotic cell death [17]. This speculatively
raises the question of immune activation against the tumour
following plasma application, and the possibility of sponta-
neous regression of metastatic tumours, as has been occasion-
ally recorded following radiotherapy [83], radiofrequency ab-
lation [84, 85] and cryotherapy [86]. Direct combination with
immunotherapy may present further synergistic prospects
[87]. As a result, it may be argued that plasma-induced cell
death via necrosis could provide the most effective long-term
treatment outcome. Should this be the case, immune check-
point inhibitors (such as nivolumab, which has very recently
demonstrated efficacy in the treatment of advanced
nonsquamous non-small-cell lung cancer and metastatic mel-
anoma [88, 89]) may present an interesting prospect for future
use in conjunction with LTP to boost tumour immunogenic-
ity. Another thought-provoking concept is the direct stimula-
tion of immune cells with LTPs, potentially increasing the
efficacy of macrophages against tumour cells [90].
Overcoming resistance to conventional treatments
with low temperature plasmas
As with any prospective new treatment, there are questions
regarding potential treatment resistance, as commonly experi-
enced with some currently applied cancer therapies. Tumour
hypoxia has been identified as one probable factor in radio-
and chemo-therapeutic resistance and tumour invasiveness
[91]. Supporting evidence has been reported recently in many
different malignancies including those of the lung [92], liver
[93], breast [94, 95] and brain [96]. Whilst direct DNA dam-
age is inflicted by energetic particles, secondary damage fol-
lowing radiotherapy is caused by the production of oxygen
radicals from the interaction of ionising X-rays and molecular
O2 in tissues and the local environment. As a result, in
oxygen-deficient regions of the tumour, lethal DNA damage
may not be achieved [97]. Hypoxia may not be so much of an
issue for LTP therapy, since the majority of LTP cancer studies
feed small admixtures of molecular oxygen (or nitrogen) into
the main gas flow to aid the production of oxidative (and
nitrosative) radicals. As such, LTP treatment could provide
oxygen radicals directly to the treatment site, circumventing
the need for endogenous O2 in the tissue (as with radiothera-
py), which may surmount the issue of hypoxic resistance. The
success of this theory would depend strongly on the means of
treatment administration and reactive species penetration,
which are discussed in the subsequent section.
CSCs have been proposed to be the root of both disease
initiation [98] and recurrence [99]. They have been widely
implicated in both radio- and chemo-resistance [100–103].
One reason for this may be higher levels of heterochromatin
in CSCs compared to the bulk population, affording added
protection against DNA damaging treatments [104]. It is also
thought that CSCs have higher levels of ROS-quenching en-
zymes in order to alleviate toxicity effects from reactive spe-
cies formation [105] more effectively than their differentiated
counterparts. Overloading CSCs with an abundance of RONS
generated by LTPs may overcome this protective shield.
Our own experimental evidence suggests that LTP can be
delivered in cytotoxic doses to CSCs. Figure 3 shows high
levels of DNA damage (quantified using the Comet assay,
based on [108]) following LTP jet treatment [17], irrespective
of cellular sub-population. Here, the cells treated with plasma
were primary prostate epithelial cells, cultured directly from
an aggressive Gleason grade 9 tumour. The cells were sorted
into sub-populations [106] and treated in suspension. Whilst
this is very preliminary data, its inclusion serves to demon-
strate the potential of LTP to induce highly significant cyto-
toxic effects in cells that are thought to be a causal factor in
treatment resistance and relapse.
Fig. 3 LTP induces DNA damage in cancer stem cells. Prostate cancer
stem cells (SC), transit amplifying (TA) and committed basal (CB) cells
were cultured and fractionated [106, 107] from a Gleason grade 9
metastatic tumour, and treated as described in Hirst et al. [17].
Statistical analysis of plasma treatments was calculated using Mann–
Whitney test against untreated samples and showed P < 0.0001
significance, unless otherwise indicated (**P< 0.01, ****P< 0.0001)
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Progress towards the clinical use of low temperature
plasmas
Many different plasma designs and geometries exist across
academic institutions, e.g. [6, 7], demonstrating a broad ver-
satility, but also highlighting the fact that direct data compar-
ison can be problematic. Standardised ‘reference’ plasma jets
are being developed across research centres to help unravel
the fundamental plasma physics and chemistry. It is also pos-
sible that different LTP sources will ultimately find different
clinical uses. Some proposed uses include intra-operative
treatment of potentially positive surgical margins following
tumour excision by surgery [37], injection of plasma-
activated media into the tumour [109, 110], and decontamina-
tion of ulcerations in advanced head and neck cancer patients
as mentioned earlier [52].
The majority of published studies in the field of plasma
oncology focus on the direct application of LTPs to tumour
cells. To fully eradicate solid tumours, the cytotoxic effect of
plasma application must be capable of penetrating several
layers of cells. A recent study on colorectal cancer cells, cul-
tured as spheroids in suspension and treated with an LTP jet,
showed a reduction in growth rate at low exposures and a
complete growth arrest at longer plasma exposures of [111].
However, only the first few outer layers of the spheroid
showed γH2AX-positive foci, suggesting that plasma-
induced cell damage was surface-limited. Another report used
agarose gel as a tissue-substitute to model the transfer of
RONS across a biologically relevant interface. Reactive spe-
cies were detected in the liquid regardless of whether the plas-
ma jet was in direct contact with the agarose or not, and even
after the plasma had extinguished [112]. This suggested that
RONS were released from the agarose, created in the liquid
environment as secondary reactions, or both, even after treat-
ment. This simple model shows that reactive species produced
by LTPs can cross a tissue-like interface (at least up to a few
mm), which when combined with a potential plasma-induced
bystander effect gives hope for cytopathic plasma-effects in
solid tumours. Despite several in vivo studies showing prom-
ising levels of tumour reduction following LTP application
[15, 45, 113], complete tumour eradication and long-term dis-
ease-free outcome remains to be proven.
The most successful method of realising an effective, focal
and minimally invasive surgical approach is likely to be pen-
etration of the plasma into the tumour core, to destroy the
cancer radially outwards. Although many tumours are multi-
focal, it has been argued that targeted treatment to only the
index lesion of a localised tumour is sufficient to provide
satisfactory disease control [114], in addition to limiting treat-
ment invasiveness. The concept of inserting the plasma
transperineally into the centre of a prostate tumour was pro-
posed in a recent review article [6], and is expanded for an
arbitrary solid malignancy in Fig. 4. We propose that this
concept should ensure enhanced targeted treatment of a tu-
mour, compared to conventional surgical or radiotherapy tech-
niques, and more controlled tumour volume destruction than
is feasible with alternative ablative techniques such as RFA or
cryotherapy.
Assuming the effects of LTP could propagate beyond a few
cell layers (be it directly or via bystander effects), precisely
monitored plasma ablation should also enable a satisfactory
clearance zone to be achieved. This implies that damage to
normal cells is not necessarily a negative feature, as a degree
of collateral damage is a more favourable consequence than
incomplete tumour ablation. Clearance margins of∼1 cm have
been suggested in some cases [115], to maximise long-term
disease-free outcome.
The propagation of LTPs in liquid environments has been
demonstrated experimentally [116], where, depending on the
operating parameters, the plasma may adopt either a bush- or
tree-like formation after generation [117]. Clearly, the degree
of relative moisture within the tumour environment will play a
role in the plasma propagation and chemistry, and is likely to
vary from tumour to tumour. Delivery of the plasma to areas
that are potentially difficult to access and penetration inside
the tumour are two of the main technical hurdles with this
Fig. 4 Illustration of LTP treatment of a tumour. In the proposed
approach, the LTP probe is inserted under needle guidance into the core
of the tumour. The plasma is then ignited, creating short-lived reactive
species (red dots) that induce DNA damage, necrosis and potentially
electroporative effects to cells in the immediate vicinity. The diffusion
of longer-lived species (blue dots) to the tumour periphery is shown,
contributing to apoptotic and plasma-induced bystander effects.
Proposed cellular effects and responses are estimated based on their
proximity to the plasma source. Gas extraction is also indicated through
a co-axial configuration in the LTP probe. Elements of this figure are
adapted from Hirst et al. [17]
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proposition; nevertheless, evidence within the literature sug-
gests both can be overcome. As plasmas can be propagated
along tubes of metres in length [118], precise LTP delivery
even to tumours deep within the body should be possible in
principle. In shorter tubes, plasmas have been sustained in
tubes as small as ∼10 μm in diameter [119]. Internal plasma
application has already been evaluated as effective and well-
tolerated in a pancreatic in vivo model [113]. As some internal
applications may require longer tubing lengths than others, the
inherently short lifetimes of the most reactive (and thus most
damaging) species may curtail their journey from source to
target. However, provided an active plasma emerges from the
end of the tube where electrons are present, short-lived species
will be created locally at the application site. This concept is
illustrated in Fig. 4, but largely depends on the plasma source
used. Regardless, a rigorous knowledge of the RONS densi-
ties emerging from the specific aperture used for application is
essential. It has recently been suggested that control and se-
lectivity towards different reactive species may be achievable
by using different feed gases [120]. Maximal lethality of treat-
ment is likely to be found by tuning the plasma operating
conditions including voltage waveform parameters, gas com-
position and treatment duration [121]. Finally, some form of
gas flow extraction (as highlighted in Fig. 4) during LTP treat-
ment would almost certainly be necessary to minimise the risk
of embolisms, and could be combined with cyclic LTP
application.
Conclusions
Earlier diagnosis and accurate targeting, combined with min-
imal damage to surrounding tissues and reduced patient side
effects, has led to increased popularity of tumour treatment
with thermal and non-thermal ablative focal therapies. Over
the last decade, LTPs have demonstrated their potential as a
novel approach in the targeted treatment of cancer. Both
in vitro and in vivo studies have shown promising results in
a wide range of different malignancies. In addition, both
modelling and experimental studies are beginning to unravel
the complex interplay of plasma-liquid-cell interphases.
Through precise application and accurate monitoring, LTPs
could offer defined and effective treatment for many tumours,
whilst minimising side effects to the patient. This review has
highlighted the multifaceted action of LTPs, through the for-
mation of a rich chemistry containing RONS and the possible
contribution of strong electric fields in biological response. It
has also speculatively outlined the potential for the application
of LTPs as a combination therapy in conjunction with other
current approaches, and how they may be able to overcome
treatment resistance. Finally, a plausible treatment approach is
presented, demonstrating how LTPs might be applied to any
arbitrary solid mass, to achieve maximum lethality to the
target lesion. It is hoped that the evidence and concepts pre-
sented in this paper have conveyed the undeniable promise of
LTP technology for the future treatment of cancer.
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